Table 1 Summary of relevant randomised controlled trials included in the review
Interventions | Study | Study design | N* | Age median (range) | Males (%) | Median duration of follow-up (weeks) | Prior therapy for advanced disease | Performance status, n (%) | STS subtypes, (%) |
|---|---|---|---|---|---|---|---|---|---|
Pazopanib 800 mg per day orally | R, DB, PC, MC-I, Phase III | 246 | 56.0 (20.0-83.0) | 40.0% | 49.5 weeks | Anthracycline: 98.8%; ifosfamide: 66.7% | PS 0: 118 (48.0); PS 1: 128 (52.0) | Leiomyosarcoma: 44.3%; Synovial sarcoma: 10.2%; Others: 45.5% | |
Placebo | Â | 123 | 51.0 (18.0-78.0) | 44.0% | 45.3 weeks | Anthracycline: 98.4%; ifosfamide: 75.6% | PS 0: 60 (48.8); PS 1: 67 (51.2) | Leiomyosarcoma: 39.8%; Synovial sarcoma: 10.6%; Others: 49.6% | |
Trabectedin 1.5 mg/m2 24-hour infusion q3w | R, OL, DR, MC-I, Phase II | 136 | 53 (20–80) | 32.4% | 177.67 weeks | Anthracycline: 100%; anthracycline and ifosfamide: 99.3% | PS 0: 70 (51.5); PS 1: 66 (48.5) | Leiomyosarcoma: 61.5%; Liposarcoma: 25.6%; Others: 12.8% | |
Trabectedin 0.58 mg/m2 3-hour infusion qw |  | 134 | 54 (23–77) | 41.8% |  |  | PS 0: 67 (50.0); PS 1: 67 (50.0) | Leiomyosarcoma: 55.5%; Liposarcoma: 37.8%; Others: 6.7% | |
Gemcitabine 1800 mg/m2 as a fixed dose infusion rate (10 mg/m2/minutes) + dacarbazine 500 mg/m2 q2w | R, BU, AC, MC, Phase II | 59 | 49 (18–78) | 53.0% | 62.83 weeks | Out of total eligible population of 109 patients 107 patients had received anthracycline and two patients had received ifosfamide | PS 0:22 (38.6); PS 1:30 (52.6); PS 2:5 (8.8) | Leiomyosarcoma: 28.1%; Liposarcoma/adipocytic sarcoma: 17.5%; Undifferentiated pleomorphic: 19.3%; Miscellaneous sarcoma: 24.6%; Synovial sarcoma: 10.5% | |
Dacarbazine 1200 mg/m2 q3w |  | 54 | 51 (25–73) | 54.0% | 60.67 weeks |  | PS 0: 17 (32.7); PS 1: 31 (51.6); PS 2: 4 (7.7) | Leiomyosarcoma: 30.8%; Liposarcoma/adipocytic sarcoma: 17.3%; Undifferentiated pleomorphic: 15.4%; Miscellaneous sarcoma: 26.9%; Synovial sarcoma: 9.6% | |
Gemcitabine 900 mg/m2 over 90 minutes, D1+D8 + docetaxel 100 mg/m2 over 60 min, D8 q21 days | R, BU, AC, MC, Phase II | 84** | - | - | Unclear | Anthracycline: 100% | - | Leiomyosarcoma: 100% | |
Gemcitabine 1000 mg/m2 over 100 minutes, d1+d8+d15 q28 days | Â | Â | - | - | Â | Anthracycline: 100% | - | Leiomyosarcoma: 100% | |
Sorafenib 400 mg twice daily orally | Pacey 2011 [28] | R, DB, PC, MC-I, Phase II | 2 | - | - | Unclear | Anthracycline and/or ifosfamide: 100% | - | Fibrosarcoma: 0.0% |
Placebo | Pacey 2011 [28] |  | 2 | 67 (62–72) | 0 |  |  | PS 0: 2 (100) | Leiomyosarcoma: 50.0%; Fibrosarcoma: 50.0% |
PS 1: 0 (0.0) | |||||||||
Ifosfamide 5 g/m2/1 day given as 24-hour infusion; all cycles were repeated q3w | van Oosterom 2002 [29] | R, BU, DR, MC-I, Phase II | 27 | - | - | Unclear | Anthracycline: 100% | - | - |
Ifosfamide 3 g/m2/day given over 4 hour on 3 consecutive days; all cycles were repeated q3w | van Oosterom 2002 [29] | Â | 31 | - | - | Â | Anthracycline: 100% | - | - |